1

CURRICULUM VITAE Name: GRIGORESCU Name: Alexandru Călin Address: Constantin Sandu Aldea Avenue # 3, block 6, ET I, AP 5, Bucharest, Romania Marital Status: Married, two children. PRESENT POSITION:

Chief of Department Medical Oncology II, Institute of Oncology Bucharest)

Habilitate doctor (Doctor authorized to lead PhD at the University Carol Davila- Bucharest)

Researcher degree I (equivalent with the title of research professor-by order of Ministry of Education no. 4,506, July 22, 2010)

Doctor in Medical Sciences (PhD) MD Medical Oncology consultant (medic primar oncologie medicala), Institute of Oncology Bucharest

Competence bronchology

Competence palliative care

Representative of Romania in ESMO Designed Centers Working Group.

National representative in the International Society of Geriatric Oncology (SIOG)

Member of the American Society of Clinical Oncology

Member of the International Society for the Study of Lung Cancer (IASLC)

President of the National Society of Medical Oncology in Romania (SNOMR)

Member of Advisory Board of the journal "Framingham on lung cancer"

Chief redactor of the editorial board of the journal "Oncolog Hematolog"

Peer reviewer to on line Faculty 1000 journal.

Peer reviewer of “Asia Pacific Journal of Clinical Oncology”

Expert in the European Commission for research project”HORIZONT2020” EDUCATION:

1974 High School "Gheorghe Lazar", Bucharest 1981 Faculty of MedicinăGenerală "Carol Davila" - Bucharest 1981 1984 Internship: Hospital "Ion Cantacuzino" – Bucharest 1984 1988 General Medicine Doctor: Jud. Bacau 1988 Pass through competition for Secondary in Oncology and Chemotherapy (Medical Oncology) Institute of Oncology Bucharest. 1991 Specialist in Medical Oncology 1991 Competence bronchology 1995 MD Medical Oncology (senior clinical adviser) 2002 Doctoral thesis Bucharest-July (PhD) 2005 Competence in palliative care

2

PROBATIONS, COURSES, EXAMS

1990 Training in bronchology National Institute of Pneumology "Marius Nasta" 1991 Exam for title of specialist in Medical Oncology 1991 Exam for the title of research in clinical oncology 1993 (Aprilie. - June.) grant in medical oncology and interventional bronchoscopy Laennek Hospital (Nantes - France) 1994 Course "Molecular Biology for clinicians" (Ascona, Switzerland) 1995 Admitted to PhD: "Advanced non-small cell lung cancer." Marius Nasta Pneumology Institute of Bucharest, scientific coordinator Prf.Dr. Emil Corlan 1995, June 20 to 26, training in endobronchial curieterapie, Hôpital Guillaume et René Laennec (Nantes, France). 1997 Exchange of good clinical practice in medical oncology "Good Clinical Practice (GSP) in Medical Oncology" - Copenhagen, Denmark, 20-25 October. 1998 Colloquium promotion as Senior Researcher III. Course ESMO 1998: "Reading, Writing and Randomised Trials" Budapest, 28-31 October. 1999-2000 Course French Romanian psycho-oncology – Bucharest, diploma graduation paper. 2001 "Training Workshop Spikers Oncology Meeting" - Prague 6 to 8 September 2002 PHD diploma , July Bucharest 2004 Passing the examination for the title of senior researcher II. - Validation no. 1201/18 02 2003 from Romania Academy of Medicine 2004 Advanced course in thoracic tumors "Rhodes / Greece June 16/19 June PROFESSIONAL ACTIVITIES:

1991 Organization of laboratory for bronchial endoscopy in Institute of Oncology Bucharest 1996 Founding member of "Central Eastern European Oncology Group" led by Professor Heine H. Hansen, Denmark. 1996-2002 Representative "ESMO (European Society for Medical Oncology) Central Eastern European Task Force". The Group had the following tasks: - Identify ways that lead to the recognition of Medical Oncology specialty in its own right, - training to organize a group of clinical trials, reflected in the establishment of "Central Eastern European Oncology Group" - Initiating activity in organizing symposiums, courses for medical oncology and oncology nursing, reflected in the organization of two courses under ESMO label in Romania - Establishing links between ESMO and the National Society for Medical Oncology. 1998 Co-organizer and lecturer of the course to European Society for Medical Oncology (ESMO): "Cytostatic agents delivery and toxicity", Sinaia, Romania. 1999 Appointed National Representative in the European Society for Medical Oncology (First National Representative of Romania in ESMO) 1999 Founding member of ESMO-PCWG (Palliative Care Working Group) 2001 President of ESMO course and lecturer for course "Reading Writing Clinical Trials" - Sinaia, Romania (5-7septembrie) 2002 Co-Chair of the Congressional session psihooncologie to European Society for Medical Oncology. (Nice / France 0ctombrie 18-22). 2003 Member of the Secretariat "Central European Lung Cancer Conference" Vienna, 1-4 septemrie. 2004 Member of the ESMO "5x5x5" educational program, 2010 The title of "ESMO designated Center for integrating medical oncology with palliative care" for Institute of Oncology Bucharest. RESEARCH: 1. Grant in Laennek Hospital (Nantes - France) Medical Oncology 1993 2. Coinvestigator international monitoring in clinical trials: "5-fluorouracil bolus or short infusion in advanced colorectal cancer" in the "Central Eastern European Oncology Group" (1998).

3

3. 2001 Project Manager Research Academy of Medical Sciences under the title: controlled clinical trial phase II Combination therapy chemo-radiotherapy to chemo-radiotherapy plus endobronchial curieterapia in inoperable lung cancer with bronchial obstruction 'with contract no. 048/22.10.2001 between Academy of Medical Sciences - UCPN VIASAN and Institute of Oncology Prof. Alex.Trestioreanu Bucharest 4. Coordinator for IOB of the research in immunology of cancer project initiated by “Institute Cantacuzino Bucharest” 5. Design and principal investigator in the national study "Gemzar Gemzar plus vinorelbine followed by ifosfamide plus Gemzar plus cisplatin compared to small cells lung cancer without advanced 6. IOB program coordinator in the grant obtained by the Medical Academy "Enhanced Treatment Malignant pleural By Termochimioterapie Intrapleorala" <H-Tech Tcip>, No. 3, 84, 2006 7. Research in the ESMO-PCWG 2000-2012.(site ESMO) 8. Research Project Coordinator Wira SA 2010 "Share tumors occur in the framework of staffs in power, especially waste Congeneration" 9. Palliative care research grant ESMO 2009, St. Galen, Switzerland 10. Representative of the National Cancer Institute Bucharest Research Project-Romania.2012-2015 Switzerland – Project “IZERZO”. 11. Representative in educational and research group of European Society for Medical Oncology (ESMO), Palliative Care Working Group (PCWG). TEACHING EXPERIENCE: 1. Lecturer in course organized by ESMO (European Society for Medical Oncology) "Cytostatic agents delivery and toxicity", Sinaia, Romania, 1998. (The first international course organized by IOB under auspices of ESMO and first class with simultaneous English-Romanian translation for medical oncologists and nurses). 2.Chairman and lecturer of the course and lecturer in the ESMO: "Reading Writing Clinical Trials" - Sinaia, Romania (5-7septembrie 2001). 3. Co-Chairman to psihooncologie session of the ESMO Congress in Nice, France 2002 4. Course Chairman and Lecturer in the ESMO: "Fundamentals in Medical Oncology", Sinaia 2003. 5. Chairman of ESMO course and lecturer: "Lung Cancer and Head and neck tumors" October 2004, Bucharest 6. Chairman and lecturer of ESMO in the course "Gastrointestinal malignancy", Bucharest 2005. 7. Chairman and Lecturer in SIOG Symposium (International Society of Geriatric Oncology) - SNOMR (National Society for Medical Oncology in Romania), Poiana Brasov 2006. 8. Lecturer at the "European School of Oncology": "Masterclass in Palliative Cancer Care", Tbilisi, Georgia, 2007. 9. Lecturer ESMO Symposium: "Palliative and Supportive care in Medical Oncology", Bucharest 2007. 10. Lecturer and Chair of "ASCO-SIOG-SNOMR Symposium" Poiana Brasov 2009 11. Chairman and lecturer of ESMO Symposium: "Update in Medical Oncology", Poiana Brasov 2010. 12. Symposium Chair and lecturer: "Palliative Care" in the "scientific Days IOB" Bucharest 2010. 13. Chairman and lecturer of "New Trend in Medical Oncology" ASCO-SNOMR Symposium, Poiana Brasov 2011. 14. Lecturer and president international symposium "Integration of Palliative Care with Medical Oncology" in "IOB scientific Days". Bucharest 2011. 15. Coordinator and lecturer in "International Symposium ASCO-SNOMR": "Lung cancer change for new therapies", 12-13 October 2012 Poiana Brasov – ROMANIA 16. ERSMO-SNOMR symposium.Breast Cancer Actual Knowledge And New Standards To Improve Survival And Quality Of Life, Symposium Coordinator: Alexandru C. Grigorescu, Poiana Brasov – Romania 18-19 October 2013 17.Lecturer in Breast Cancer course organized by National Society for Surgery of Romania., Sinaia , mai 2014 18. Lecturer in the course “Multimodal treatment of advanced rectal cancer” organized by National Romanian Society for surgery.Sinaia mai 2014 19. Lecturer and Event coordinator of ESMO-Labelled Meeting “SOME CURRENT DATA IN MEDICAL ONCOLOGY” Poiana Brasov –Romania –09 October 2015

4

MAIN TRIALS:

Programul / Proiectul Funcţia Perioada

Phase II study: Gemcitabine monotherapy in advanced non small lung cancer, Elly Lilly 1997

Sub investigator 1997 -1999

5 Fluorouracil in shot perfusion versus bolus administration, Central Eastern European Oncolgy Group 1998

Principal investigator 1998- 1999

Phase III international study of oral Topotecan in second line of advanced small cell lung cancer, Glaxo-Smithkline 2001

Principal investigator 2001-2003

Studiu de faza a II-a, Gemcitabina plus cisplatin versus gemcitabina plus vinorelbina urmata de gemcitabina plus ifosfamida in administrare secventiala 2002, Elly Lilly

Principal investigator 2002 -2004

Studiul international ChEST, Preoperator chemotherapy in Early stage non small cell lung cancer, Elly Lilly

Principal investigator 2003-2005

Studiul de faza a II-a, randomizat privind administrarea de extract de 4 ecidiva pentru ameliorarea durerii în cancerul avansat. 2004

Principal investigator 2004

Studiul international de faza a IV-a privind chimioterapia de faza a II-a cu tarceva., Roche.

Principal investigator 2005-prezent

Studiu clinic controlat de faza a II-a privind tratamentul asociat chimio-radioterapic fata de chimio-radioterapia plus curieterapia endobronsica în cancerul bronho-pulmonar inoperabil cu obstructie bronsica care face obiectul contractului nr. 048/22.10.2001 încheiat între Academia de stiinte Medicale – UCPN VIASAN si Institutul Oncologic Prof.dr. Alex.Trestioreanu Bucuresti

Project director 2002- 2004

Studiul international de faza a II-a privind hormonoterapia cu inhibitori selectivi de aromatază în cancerul mamar 4 ecidivate sau metastatic. (2005).Intarcia –USA

Principal investigator 2005-2006

Coinvestigator în studiul privind administrarea de anticorpi monoclonali (removab) pacientilor cu ascita neoplazică refractară la citostatice (2005),Fressenius –Germania

Subinvestigator 2005-2007

Tehnologie avansata de tratament a pleureziilor maligne prin termochimioterapie intrapleurala,

Nr. 3 / 84 / oct. 2006

Project coordinator for IOB site

2006- 2009

A Multi-center , Randomized , duble-blind , Placebo-controlled, Phase 3 Study bof Single –agent Tarceva folowing Complete Tumor Resection and with or without Adjuvant chemotherapy in patients with Stage IB-IIIA Non –Small Cell Luna Carcinoma who have EGFR –Posiotive Tumors

Principal investigator 2007-2008

A randomized withdrowal, active –and placebo –controlled , double –blind, multi-center Phase III trial assessing safety and efficacy of oral

Principal investigator 2007-2008

5

CG5503 PR in subjects with moderate to severe chronic malignant tumor- related pain. –Grunenthal

Phase 2, randomized, open lebel, multicenter study of intradermal IMA 901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease- Immatics

Principal investigator 2007-2008

A Randomiyed Duble blind Multicenter study of Denosumab Compared with Zolendronic Acid in the Treatment of Bone Metastasis in Men with Hormon –refractarz prostate cancer.

Principal investigator 2008+2009

Studiu nonintervenţional Eligard 7,5 mg şi 22,5 mg pentru tratamentul cancerului avansat de prodtată hormonodependent

Principal investigator 2009

Stiudiul DMS32212R - cancer bronhopulmonar avansat

Principal investigator 2009-2010

Studiul ML 20951, Tarceva (studiu original la propunerea investigatorului principal)

Principal investigator 2009-2010

Phase 2 randomized study of carboplatin /paclitasxel with or without CS -7017 in chemotherapy –naive subjects with metastatic non-small cell luna cancer, CS7017-A+U202

Principal investigator 2010-2011

Studiul IUNO, (Erlotinib in cancerul bronhopulmonar metastatic)

Principal investigator 2012-2013

Study FLAURA: AZD9291 in TKI rezistent lung cancer

Principal investigator 2014-2016

Study NERO Principal investigator 2017-2018

Merck EMD Serono EMR 100070-005

Principal investigator 2017-2018

Main original contributions 1. The first global study of phase III published that compare combinations of chemotherapy: Gemzar plus carboplatin compared to cisplatin plus vinblastine. - Confirmed editorial Professor Maurizio Tonato-Lung Cancer 2002 - Chapter III.2. 2. The first study in Romania on endobronchial brachytherapy associated with chemotherapy - Contract Viasan 048 of 30 October 2001 - Chapter XIV 3. The first book in Romania on good clinical practice in clinical trials in oncology. Life Review in SANATATEA, Prof. Dr. Eduard Bild-Chapter V.1 4. The first study reporting cases by Internet of Institute of Oncology Bucharest 5. Representative of Romania and founding member of "ESMO-Central Eastern European Task Force" - 1996 -2006 6. The first representative of Romania in the European Society of Medical Oncology 1999

6

7. First Romanian representative the International Society of Geriatric Oncology: SIOG. 8. The first representative of Romania and founding member of the Group for palliative care ESMO: ESMO-PCWG. 9. The first member of Romania in geriatric oncology group study of the EORTC (European Organization for Reseatch and Treatment of Cancer). 10. Organizing the first international course in medical oncology in the Institute of Oncology Bucharest. 11. Bronchology Cabinet Organization of Institute of Oncology Bucharest. 12. The first medical oncologist who has acquired expertise in bronchology in Romania. 13. Publication of the first book in palliative care with an international team of authors at the Institute of Oncology Bucharest. 14. Founding member of "Central Eastern European Oncology Group" 15. The first research grant under the European Society of Medical Oncology achieved. in Institute of Oncology Bucharest 16.Optaining the Diploma of ESMO for Institute of Oncology Bucharest (IOB) like ESMO Designated Center for integration of Medical Oncology with Palliative Care. Publications

Communications in conferences: 1. Problems of bronchoscopy in diagnosis of lung cancer - Colloquium Romanian - French Pneumology, Bucharest, October 1991. 2. Evolving clinical and therapeutic aspects in carcinomatous mastitis, Grigorescu Alexander Mogoş Ion, Done {Serban, Doina Spataru Conference naţionalăde oncology, Craiova 8 to 9 October 1992. 3. Diagnosis and treatment of advanced lung cancer, Alexandru Grigorescu, John Mogoş, {Serban done, Dana Stănculeanu, Scientifically days of Institute of Oncology Bucharest 1993. 4. The combination of radiotherapy and chemotherapy in NSCLC. Alexandru Grigorescu, Maricica Palade, Mircea Savu, Anton Ionescu, Days radiotherapy, Bucharest May 24 to 25, 1994 5. CEA and CA125 in the diagnosis, monitoring and development of NSCLC. Alexandru Grigorescu, Eliza Mănoiu, Nicholas Stafidov, Days radiotherapy session of IOB. 26 to 27 May 1995 6. Pilot study on the use of interferon in aerosols or introduced by bronchoscopy in the treatment of obstructive endobronchial neoplastic syndrome, Alexandru Grigorescu, naţionalăde Oncology Conference, Poiana Brasov, 24-25 October 1996. 7. Chemotherapy versus chemotherapy associated with biphosphonates in the treatment of pain in lung cancer with bone metastases, Alexandru Grigorescu, IOB ştiinţifică anualăa Session, 29-30 May 1997. 8. Polychemotherapy regimens in non small cell lung cancer, administration protocol, tolerance, toxicity. Alexandru Grigorescu, National Cancer Congress, Poiana Brasov, 1997. 9. Randomized phase II trial: chemotherapy of carboplatin plus gemcitabine versus cisplatin and vinblastine in advanced NSCLC. Alexandru Grigorescu, Nicolae Guţulescu, National Congress of Oncology, Bucharest October 14 to 16, 1999.

7

10. Open clinical study on the influence of chemotherapy on quality of life and survival of patients with advanced lung cancer, Alexandru Grigorescu Nicolae Guţulescu. 11. Combination chemo-radiotherapy in mediastinal compression syndrome in cancer, Alexandru Grigorescu, Xenia Bacinschi, Alin} Arle, first conferinţănaţionalăde medical oncology, Craiova - Căciulata 11 to 14 April 2002. 12. Ioan Popa, Alexandru Calin Grigorescu, Michael Gr Mark, Mona Marin ,Study of risk factors and survival in chronic diseases - statistical approach, Conference anniversary of the Institute of Public Health, Bucharest, June 12 to 13, 2003. 13. Grigorescu, T. Ciuleanu, Elena Firoiu, Delia Muresan, C. Davidescu, M. Ciochinaru, R. Curca, Roberta Rosca, Gabriela Teodorescu ,Sequential combination of gemcitabine plus vinorelbine followed by gemcitabine versus gemcitabine plus ifosfamide plus cispaltin in the treatment of non-small cell lung cancer stages III and IV, preliminary results of a randomized phase II study. National Conference of Oncology, Durau, 10 - September 14, 2003, p34. T. A. 14. Doina Spataru, A. Grigorescu, Comparative study of adjuvant chemotherapy with 5 fluorouracil versus polychemotherapy in stage III gastric cancer, Scientifically days of Institute of Oncology Bucharest November 2003. 15. Continuous infusion devices used in chemotherapy of digestive malignancies. Scientifically Days of Institute of Oncology "Prof. Dr. Ion Chiricuţă» 9 to 10 October 2003. 16. "Organizing a center for clinical trials," communication training sessions continue in IOB. November 2003. Romanian Journals: 17. Alexandru Grigorescu, Assessing value of endoscopic bronchial issues in bronhopulonar cancer evolution and prognosis., "Oncology and Radiotherapy" - Vol XXXII No. 1-1994, p 63 18.Alexandru Grigorescu, Constance Chiritescu, Endoscopic and citohistologic elements of association: inflamator-cronic syndrome - bronhopulonar cancer, "Oncology and Radiotherapy" Vol XXXII, NO. 1, 1995, p 75-78. 19.Alexandru Grigorescu Nicolae Guţulescu, Delia Marta, {Serban Donea, Phase II study of the etoposide plus cisplatin and ciclifosfamid in advanced lung cancer, "Oncology and Radiotherapy" Vol XXXII, NO. 2-3, 1995, p 35-40. 20. Alexandru Grigorescu, Eliza Mănoiu, Nicholas Stafidov, CEA and CA 125 in the diagnosis and monitoring of lung cancer treatment" Oncology and Raditherapy" 1996, vol 333 NO. 1, p 53-56. 21.Alexandru Grigorescu, impact of chemotherapy on quality of life of patients with advanced lung cancer, "Oncology and Radiotherapy" vol XXXII, 1996, NO. 2 to 3, p73-77. 22.Alexandru Grigorescu, recent data in the treatment of advanced lung cancer, "Clinical Toxicology”, Vol II, No. 1, 1998, p 117. 23.Alexandru Grigorescu, colon cancer with liver metastases, case presentation. "Romanian Oncology Review", vol XXXVI, NO. 1, 1999, P105. 24.N. Gutulescu, A.Grigorescu, D.Uta, A. Sherer, L Gebez, K.Krejcy, Gemcitabine in advanced lung cancer

8

, Romanian Journal of Oncology, Volume XXXVI, No. 2, 1999, p 25. 25.Nicolae Guţulescu, Alexandru Grigorescu, Paclitaxel with cisplatin in NSCLC, Revista Romana de Oncologie, vol 36, no. 3, 1999, p :268-271. 26.A.Grigorescu, N. Draghici, N. Gutulescu, Taxol versus radiotherapy alone with radiotherapy in non-small cell lung cancer - pilot study, Supplement of Radiotherapy and Medical Oncology, Vol 36, No. 2, 1999. 27. Alexandru Grigorescu, Nicolae Guţulescu, Quick diagnosis and treatment of lung cancer, Romanian Journal of Oncology, Vol 37, No.1, 2000, p :15-23. 28.Alexandru Grigorescu, Niculina Draghici, Cornelia Niţipir, Nicholas Guţulescu, Emil Corlan, gemcitabinăşI carboplatin chemotherapy with cisplatin and vinblastine in non small advanced lung cancer, stage III and IV controlled clinical trial phase III, Info medication, 9 / 2001, p: 40-45. 29.Alexandru Grigorescu Nicolae Guţulescu, Emil Corlan, open clinical study on the influence of chemotherapy on quality of life and survival of patients with lung cancer advanced (stages III and IV), Journal Românăde Oncology, vol 38, no. 2/2001, p :91-98. 30.Marilena Dinulescu Alexandru Grigorescu, Prevalence of microbial agents in bronchial aspirates in subjects with lung neoplasm, first Congress Foundation in collaboration with the Clinical Laboratory of Microbiology, Mamaia 29-May -25 June 2002. 31.Translation of ESMO guidelines “Romanian Journal of Oncology”, March 2004. 32.A. Grigorescu, N. Wales pleurisies treatment of malignant lung cancer, Hematology Oncologist rev # 4 - 2008. 33. A. Grigorescu, News in the treatment of malignant melanoma, Oncolog Hematolog No. 3-2009. 34. A. Grigorescu, Chemotherapy of lung cancer in the elderly, Oncolog Hematolog, Year III, No. 6 March 2009, p 18-21. 35. A. Grigorescu, News in treatment of advanced gastric cancer, Oncolog Hematolog, Year III, No. 7 (2) 2009 36.A. Grigorescu, News in therapy of small cell lung cancer, Oncolog Hematolog, Year III, nr.9.4/2009 37.A. Grigorescu, Current clinical research in melanoma, Oncology Hematolog, Year III, nr.8.3 2009, pŞ26-28. 38. A. Grigorescu,"Policy of small steps", Hippocrates, December 2009, p 37. 39. A. Grigorescu, Clinical and therapeutic approach in refractory dyspnoea, Oncolog Hematolog, year IV, nr.13-4/2010 40. A. Grigorescu, Colon cancer chemotherapy, oncology, hematology, Year IV, 12.3/2010 41. A. Grigorescu, Targeted therapy in advanced renal cancer. Oncolog Hematolog, Nr14, 1/2011, p.23-25 42.A. Grigorescu, The management of advanced prostate cancer.Oncolog Hematolog, 15. 2/2011, p 16-18. 43.A. Grigorescu, Updates in small cell lung cancer therapy, Oncolog Hematolog, Nr20, 3/2012, p 32-34. 44. A. Grigorescu, International Symposium ASCO-SNOMR, Oncolog Hematolog 21. 4/2012.p. 12-13. 45. A. Grigorescu, "The success of failure" - Center for Integration of palliative care in medical oncology in the Institute of Oncology Bucharest, NR4 Hippocrates, December 2012. P20-23. 46. Alexandru Grigorescu, Immunotherapy in Lung Cancer, Oncolog Hematolog, Anul XI • Nr. 40 (3/2017) 47. Cancer fatigue – diagnosis and treatment, Oncolog-Hematolog,Anul XI • Nr. 41 (4/2017) Book Chapters: 48. Alexander C Grigorescu, "Breviary of diagnosis and treatment of advanced lung cancer," Ed Bacovia, Bacau 2000, p 1-172. 49. Alexander C. Grigorescu, "Breviary of diagnosis and treatment of advanced lung cancer," second

9

edition, Ed "Cartex 2000", Bucharest 2003.p 1-192. 50. Alexandru Grigorescu, Rodica Anghel and all, Principles of clinical trials in oncology, Ed Carol Davila – Bucharest 2006, p3-235. 51. Alexandru Grigorescu: "Respiratory Problems in" ESMO Hand book of Advanced Cancer Care ", Taylor & Francis Books Ltd, 2006, P97-104 52. Alexandru Grigorescu, Heine Hansen, Rodica Anghel,and all "ESMO Head and neck course, thoracic tumors," Carol Davila - Bucharest 2006, 1-238 53. Alexandru Grigorescu, Hans Joachim Small, Rodica Anghel, and all. "ESMO course, gastrointestinal malignancy," Ed Carol Davila, Bucharest 2007, 3-283 54. Alexandru Grigorescu, Nathan Cherny, Dana Stănculeanu and all"Palliative and supportive care in Medical OncologyŢ Ed Carol Davila Bucharest 2007, p3-11.p3-201 55. Alexandru Grigorescu, Medical Treatment of Advanced Lung Cancer, Editura Medicala, Bucharest 2008, p3-173 56. Alexandru Grigorescu, Lodovico Balducci, Florinel Badulescu, and all, 'Update in Medical Oncology Editura Medicala - Romania, 2011.p11-254. 57. Alexandru Grigorescu, Management of Chemotherapy Complications in Gynecological Malignancy Treatments, Ali Ayhan, Nicholas Reed, Murat Gultekin si Polat Dursun.,Textbook of Gynaecological Oncology, “ Gunes Publishing’ 2016.

International Journals 58. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M, Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Tuncay Goksel, Keunchil Park, Vera Gorbunova, Ruben Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey V Orlov, Conrad R Lewanski, Michael Thomas, Paolo Bidoli, Shaker Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, Maurice Péro Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, The Lancet, June 2014, DOI 10.1016/s0140-6736(14)60845 59. N. Magaya-Kalbermatten1, P. Achimas-Cadariu2, R. Curca3, A. Grigorescu4, D. Mosiou5, V. Poroch6, F. Strasser1PKEY INTERVENTIONS OF PALLIATIVE CANCER CARE (KI-PCC) - PATIENT PERCEIVED NEED AND REMEMBERED DELIVERY... Article in Annals of Oncology · September 2014, DOI: 10.1093/annonc/mdu350.11 60.Alexandru C. Gigorescu, Ioana N. Drăghici, Cornelia Niţipir, Nicolae Guţulescu, Emil Corlan,

Gemcitabine(GEM) and carboplatin versus cisplatin (CDDP) and vinblastin (VLB) in advanced non-small –cell lung cancer (NSCLC) stages III and IV: a phase III randomized trial, LUNG CANCER 37(2002) 9-14. 61. Ciuleanu T

1, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir

HK, Klughammer B, Gonzalez EE Lancet Oncol, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study, 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.

10

62. Alexandru C. Grigorescu, Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest, JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / JAN-MAR 2015 / VOL 3 | ISSUE 1, 10.4103/2224-4018.154291, 63. Alexandru C. Grigorescu ,Short Review of “Phase II Study of Erlotinib Plus Gemcitabine in First-Line Treatment of Poor Prognosis, Advanced Non-Small Cell Lung Cancer(NSCLC) Patients”- 8 Years Letter, World Journal of Research and Review (WJRR), ISSN:2455-3956, Volume-2, Issue-5, May 2016 Pages 15-17 64. Alexandru C. Grigorescu, Pemetrexed in third and fourth line chemotherapy for non-squamous non-small cell lung, Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 5(2) pp. 093-097, February, 2017 Available online ttp://www.meritresearchjournals.org/mms/index.htm Copyright © 2017 Merit Research Journals Original Research Article 65. A. C. Grigorescu, O.G. Negrea, D. Spătaru, Letters to editor, JURNAL OF B.U.ON., VOL 8, NO 2, APRIL- JUN 2003, 193. (IF=0,6) 66. Nathan I. Cherny M.B.B.S.1,‡,§,Raphael Catane M.D.2,§, Maurizio Tonato (Policlinico Divisione Oncologia Medica, Perugia, Italy); K. Winand Lange (Johanniter–Krankenhaus Rheinhausen, Duisburg, Germany); Herbert Kappauf (Institut für Medizinische Onkologie, Nürnberg, Germany); ALEXANDRU–CALIN GRIGORESCU (Oncologic Institute of Bucharest, Bucarest, Romania); Sergei Tjulandin (Cancer Research Center, Moscow, Russia); Piotr Siedlecki (Marie Skledowska–Curie Institute Cancer Center, Warszawa, Poland); Marco Maltoni (Department of Medical Oncology, Pierantoni Hospital, Forlfi, Italy); Marianne Kloke (Universitätsklinikum Essen, Essen, Germany); Kaija Holli (Department of Oncology, University Hospital, Tampere, Finland); Vladimir Bryuzgin (Cancer Research Center, Moscow, Russia); Dirk Schrijvers (Middelheim Hospital, Antwerp, Belgium); Özgür Özyilkan (Baskent University Faculty of Medicine, Ankara, Turkey); Martin Chasen (Richard Eek Sandton Oncology Centre, Pretoria, South Africa); Maria Wagnerova (University Teaching Hospital, Kosice, Slovak Republic); Janos Szanto (Debrecen Medical University, Debrecen, Hungary); and Joao Oliveira (Istituto Portugues de Oncologia, Losboa Codex, Portugal). Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer† Report on a survey by the European Society of Medical Oncology taskforce on palliative and supportive care, CANCER, VOLUME 98, ISSUE 11, PAGES 2502–2510, 1 DECEMBER 2003 67. N. I. Cherny, R. Catane, P. A. Kosmidis and Members of the ESMO Palliative Care Working Group

,

Introduction by Heinz Ludwig, ESMO President, Policy on supportive and Palliative Care, M. Tonato, Policlinico Divisione Oncologia Medica, Perugia, Italy; M. Maltoni, Pierantoni

Hospital Department of Medical Oncology, Forlì, Italy; K. Winand Lange, Johanniter-Krankenhaus Rheinhausen, Duisburg, Germany; H. Kappauf, Institut für Medizinische Onkologie, Nürnberg, Germany; M. Kloke, Universitätsklinikum Essen, Essen, Germany; A.-C. Grigorescu, Oncologic Institute of Bucharest, Bucharest, Romania; S. Tjulandin, Cancer Research Center, Moscow, Russia; V. Bryuzgin, Cancer Research Center, Moscow, Russia; P. Siedlecki, M. Skledowska-Curie Institute Cancer Center, Warsaw, Poland; K. Holli, University Hospital Department of Oncology, Tampere, Finland; D. Schrijvers, Middelheim Hospital in Belgium, Antwerp, Belgium; Ö. Özyilkan, Baskent University Faculty of Medicine, Ankara, Turkey; M. Chasen, R. Eek Sandton Oncology Centre, Pretoria, South Africa; M. Wagnerova, University Teaching Hospital, Kosice, Slovak Republic;J. Szanto, Debrecen Medical University, Debrecen, Hungary; and J. Oliveira, Istituto Portugues, de Oncologia, Lisboa Codex, Portugal, Esmo.orgESMO, 2004

68. Iuliana Caras Æ A. GRIGORESCU Æ Crina Stavaru, D. L. Radu Æ I. Mogos Æ G. Szegli Æ Aurora

Salageanu,Evidence for immune defects in breast and lung cancer patients, CANCER IMMUNOLOGY, IMMUNOTHERAPY,DECEMBER 2004, VOLUME 53, ISSUE 12, PP 1146-1152, CITED BY 57 - RELATED ARTICLES 69. Alexandru Grigorescu. Tudor Ciuleanu, Elena Firoiu A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus gemcitabine plus ifosfamide versus gemcitabine

11

plus cisplatin in the treatment of chemo-naïve patients with stage III and IV non-small cell lung cancer(NSCLC), LUNG CANCER 2007 AUG; 57(2): 168 -74, EPUB 2007, APR30 70. Ardizzoni, Andrea

1; Razis, Evangelia

2; Lichinitser, Mikhail

3; Yilmaz, Ugur

4; Grigorescu, Alexandru C.

5;

Morero, José Luis6; Skrickova, Jana

7; Cervantes, Guadalupe

8; Gottfried, Maya

9; Van Meerbeeck, Jan

10,

Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): B3-06, International Journal of Radiation On, Volume 78, Issue 5 , Pages 1407-1412, 1 December 2010,IF: 4,524 71. Cherny NI; on behalf of the Palliative Care Working Group of the European Society for Medical OncologyNathan I. Cherny (Chair, Israel), Raphael Catane (Israel), Martin R. Chasen (Canada), Alexandru‐ Calin Grigorescu (Romania), Marianne Kloke, (Germany), Ian Olver (Australia), Ozgur Ozyilkan (Turkey), Gudrun Marie Ilse Pohl (Austria), Carla Ripamonti (Italy) Maryna Rubach (Poland), Tamari Rukhadze (Georgia), Dirk Schrijvers (Belgium), Anna‐ Marie Stevens (United Kingdom), Florian Strasser (Switzerland), Maria Wagnerova (Slovakia). Factors influencing the attitudes and behaviors of oncologists regarding the truthful disclosure of information to patients with advanced and incurable cancer. PSYCHOONCOLOGY. 2010 SEP 28. [Epub ahead of print] 72. S. Tanneberger1, K. Hegedus, A. Grigorescu, J. Luczak, G.Biasco & F. Cavalli, Medical oncology recognized at EU level to allow free movement of doctors: progress and challenge, ANNALS OF ONCOLOGY ADVANCE ACCESS PUBLISHED APRIL 28, 2011 73. Dr Tudor Ciuleanu MD, Lilia Stelmakh MD b, Prof Saulius Cicenas MD c, Skaidrius Miliauskas MD d, Prof ALEXANDRU CALIN GRIGORESCU SR e, Carina Hillenbach MSc f, Hrefna Kristin Johannsdottir PhD f, Barbara Klughammer PhD f, Prof Emilio Esteban Gonzalez MD g, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study, THE LANCET ONCOLOGY, VOLUME 13, ISSUE 3, PAGES 300 - 308, MARCH 2012 74. A. C. Grigorescu, C. Bala, Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients, J BUON 2013; 18(1): 188-194 ISSN: 1107-0625 www.bu-on.org/jbuon REZUMATE ÎN VOLUMELE CONFERINȚELOR INTERNAȚIONALE, REVISTE INDEXATE IN BAZE DE DATE INTERNAȚIONALE, RECENZII, PEERREVIEW -uri PUBLICATE ÎN REVISTE INDEXATE IN BAZE DE DATE INTERNAȚIONALE 75. PC (Paclitaxel, Cisplatin) or MECC (Metotrexat, Epirubicine, Cyclophosphamide, CCNU as a Second Line Treatement for Non small Cell Lung Carcinomas (NSCLC). Abstract – Annals of Oncology, vol. 7, 1996, Supp 5 NR. 492, p 103. 76. Nonmorphinic analgesic combinations in pain treatment for cancer.European Journal of Cancer, vol. 35 Supp 4, Sept. 1999, a. 98. 77. Gemcitabine plus carboplatin (GCB) versus cisplatin plus vinblastin (CV) in stage IIIB-IV non-small cell lung cancer (NSCLC). Annals of oncology, vol 11, 2000, sup 4, abstract 499, p110. 78. Gemcitabine plus Carboplatin (Gcarb) versus Cisplatin plus Vinblastine (CV) in Patients (pts) with

Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC), A.C. Grigorescu1, I.N. Draghici1, N. Gutulescu1,

E. Corlan2, Citation: European Journal of Cancer Vol 37, Suppl. 6, October 2001, page 21 79. L. Onet, A. Grigorescu, Symptomatic treatment improve quality of life of patients with lung cancer, Citation: European Journal of Cancer Vol 37, Suppl. 6, October 2001, page 442

12

80. I. Pană, A. Grigorescu, Medical Oncology in Romania, Newsletter, 1/1996, p:7 81. Alexandru Grigorescu, “Course report: Cytostatic Agents – delivery and toxicity, an ESMO – EONS Course, Newsletter, 1/1999,p9. 82. Course report: Reading, Writing and Randomised Trials, Newsletter, 2/2001,p:7. 83. Alexandru Grigorescu, “Case report”, “Practical demonstration of pomps and I.V. lines”, “Controversial ways of administration i.p., i.a.”, în volumul “ESMO-EONS Course”: “Cytostatic Agents – delivery and toxicity, Sinaia Romania 1-3 octombrie 1998. 84. Alexandru Grigorescu, “Need for strategies in Evidence Based Medicine”, în volumul:”Reading, Writing and Randomized Trials”, Sinaia Romania, mai 2-5, 2001. 85. A. C. Grigorescu, N. I. Drăghici, L. M. Minea, N. Guţulescu, Gemcitabine (GEM) plus carboplatine (CBDCA) in sequential administration after etoposide (VP16) plus cisplatin(CDDP):a phase II study. American society of clinical oncology, vol 21, part 2 of 2, p 237b. 86. Alexandru Grigorescu, Roxana Pristavu, Nicolae Guţulescu, Influence of depression (D) in evolution of advanced non-small cell lung cancer (ANSCLC) treated by chemotherapy with cisplatin (CDDP) plus etoposid (VP16) or Gemzar (G) plus carboplatin I, Annals of Oncology, vol 13,2002 Su8pplement 5,p186. 87. Alexandru C. Grigorescu, Roxana Pristavu, Tewodor Georgescu, Phase II studz of carboplatin()CBDCA) intravenous administration plus etoposid (VP16) in oral administration for patients (pt) with advanced non-small cell lung cancer (NSCLC), Annals of Oncologz, Supplement 3, vol 14, 2003. 88. Tudor Ciuleanu, Elena Firoiu, Alexandru Calin Grigorescu, Delia Ruta Muresan, Cristian Davidescu, Mihai Ciochinaru, Razvan Curca, Roberta Rosca, Gabriela Teodorescu, Tomas Scacel, Sequential Combination of Gemcitabine Plus Vinorelbine Followed bz Gemcitabine Plus Ifosfamide Versus Gemcitabine Plus Cisplatin in the Treatment of Stage III and IV Non- Small Cell Lung Cancer, Preliminarz Results of a Randomiyed Phase II Trial, Lung Cancer, vol 41, Supplement 2, August 2003, S 224. 89. Alexandru Calin Grigorescu, Claudia Bala, Ioan Popa, Nicolae Gutulescu, Correlation between overall survival and some characteristics of long survivors with advances non small lung cancer (NSCLC) stages IIIB and IV, a retrospective study, Lung Cancer, vol 41, Supplement 2, August 2003, S 288. 90. Course report “Fundamentals in Medical Oncology”, ESMO News Letter 2004 91. Brachytherapy plus chemotherapy in advanced non small cell lung cancer (NSCLC), Lung Cancer supplement, IX 2005, p76. 92. G. Teodorescu, T. Ciuleanu, A. Grigorescu, E. Firoiu and D. Ruta Muresan, P382 A randomized phase II trial of sequential gemcitabine plusvinorelbine followed by gemcitabine plus Ifosfamide versus gemcitabine plus cisplatin in the treatment of chemonaïve patients with stage III and IV non-small cell lung cancer (NSCLC), lung cancer, vol 49, suppl 2, july 2005, p382, page s271 93. Platinum based chemotherapy for patients (Pt) with Non Small Cell Lung Cancer

(NSCLC) with anemia treated with Eupoetin beta or blood transfusion, a pilot study, Annals of Oncology, vol 14,2006 Su8pplement 4,p136 94.Andrea Ardizzoni

1, Evangelia Razis

2, Mikhail Lichinitser

3, Ugur Yilmaz

4, Alexandru C. Grigorescu

5,

José Luis Morero6, Jana Skrickova

7, Guadalupe Cervantes

8, Maya Gottfried

9, Jan Van Meerbeeck

10,

ASCO abstract Book 2009.

13

95.Alexandru Grigorescu post peer review , DOI: 10.3410/f.718389158.793495548, 02 Jun 2014 ,Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H,Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial, Lancet Oncol. 2014 Jun; 15(7):713-21 96. Alexandru Grigorescu post peer review, DOI: 10.3410/f.718415927.793495708, 02 Jun 2014, Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ,A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer, Eur J Cancer. 2014 May 21 97.Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718315380.793493332, 08 Apr 2014 ,Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Menter A, Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience, J Thorac Oncol. 2014 Mar 13 98. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718258092.793490636, 11 Mar. 2014, Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW, Riely GJ,Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC,Ann Oncol. 2014 Feb; 25(2):415-22 99.Alexandru Grigorescu ,post peer review , DOI: 10.3410/f.718163663.793491857 ,14 Mar 2014, Yin AA, Cai S, Dong Y, Zhang LH, Liu BL, Cheng JX, Zhang XA meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patient, J Neurooncol. 2014 Jan; 116(2):315-24 100.Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718140888.793489232, 14 Jan 2014, Bernards N, Creemers GJ, Nieuwenhuijzen GA, Bosscha K, Pruijt JF, Lemmens VE,No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy,Ann Oncol. 2013 Dec; 24(12):3056-60 101.Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718106825.793486609,08, Nov 2013 Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators,Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, Lancet Oncol. 2013 Oct; 14(11):1077-85 102.Alexandru Grigorescu ,post peer review, DOI: 10.3410,/f.718026266.793481159 27 Aug 2013,Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM, Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial, J Thorac Oncol. 2013 Jul; 8(7):930-939 103.Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718019529.793481158, 09 Aug 2013, Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol. 2013 Jul; 14(8):741-8 104.Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718026279.793482141, 19 Aug 2013, Fietkau R, Lewitzki V, Kuhnt T, Hölscher T, Hess CF, Berger B, Wiegel T, Rödel C, Niewald M, Hermann RM, Lubgan D , A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: Results of a randomized, controlled, multicenter trial, Cancer. 2013 Jun 13

14

105. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718016207.793479525, 18.Jul 2013 Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI,Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial, Lancet Oncol. 2013 Jun; 14(7):663-70 106. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.717973653.793479424,18 Jul 2013 Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D, Isakoff S, Ciciliano J, Wells M, Shah A, Concannon K, Donaldson M, Sequist L, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber D, Maheswaran SCirculating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition, Science. 2013 Feb 1; 339(6119):580-4 107. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718106504.793483715, 24 Sep 2013Azmi A, Sarkar F, Hadi S,Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property [v1; ref status: indexed, http://f1000r.es/15s]. 108. Valentin Titus Grigorean1, Gabriela Rahnea Niță2, Aurelia Mihaela Sandu3,Alexandru Grigorescu4, Anda-Natalia Ciuhu5, Mihai Popescu6, Blockage Of Communication With The Patient’s Family – Clinical And Psycho-Emotional Implications, Acta Medica Transilvanica March 2014;2(1):127-130 109. Alexandru Calin Grigorescu, Long-term survivors in advanced non-small cell lung cancer treated sequentially with cytostatic drugs and erlotinib: A retrospective study Journal of Translational Internal Medicine, ISSN 2224,, Vol 2 | Issue 2 | Apr-Jun 2014, p 83-86 401 ISSN 2224-4018 110. Alexandru Calin Grigorescu, Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest, Journal of Translational research, Issue 1, Jan-Mar 2015,p24-28. 111. Alexandru Calin Grigorescu review, DOI: 10.3410/f.725638359.793508418 A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H,Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K 112. Alexandru Calin Grigorescu, review (DOI: 10.3410/f.731932336.793537702): Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.Vahl JM, Friedrich J, Mittler S, Trump S, Heim L, Kachler K, Balabko L, Fuhrich N, Geppert CI, Trufa DI,Sopel N, Rieker R, Sirbu H, Finotto S 113. Alexandru Calin Grigorescu review (DOI: 10.3410/f.727384522.793529715) Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. Okamoto I, Schuette WH, Stinchcombe TE, Rodrigues-Pereira J, San Antonio B, Chen J, Liu J, John WJ,Zinner RGshow author affiliations Curr Med Res Opin. 2017 Mar 12; 33(5):1-5 114.Alexandru Calin Grigorescu, DOI: 10.3410/f.718106825.793486609, Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N,Waterkamp D, Saunders MP, AVEX study investigators show author affiliations Lancet Oncol. 2013 Oct; 14(11):1077-85

Alexandru Calin Grigorescu